{"nctId":"NCT02656875","briefTitle":"A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain","startDateStruct":{"date":"2015-12"},"conditions":["Acute Pain"],"count":768,"armGroups":[{"label":"TRV130","type":"EXPERIMENTAL","interventionNames":["Drug: TRV130"]}],"interventions":[{"name":"TRV130","otherNames":["oliceridine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria include:\n\n* Moderate to severe acute pain for which parenteral opioid therapy is warranted\n* Able to understand and comply with the procedures and study requirements, and to provide written informed consent before any study procedure.\n\nExclusion Criteria include:\n\n* Clinically significant medical, surgical, postsurgical, psychiatric or substance abuse condition or history of such condition that would confound the interpretation of safety, tolerability, or efficacy data in the study.\n* Hemodynamic instability or respiratory insufficiency.\n* Advanced cancer in palliative or end-of-life care.\n* Another current painful condition (other than acute pain for which parenteral opioid therapy is warranted) that would confound the interpretation of safety, tolerability, or efficacy data in the study.\n* Clinically significant, immune-mediated hypersensitivity reaction to opioids.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients That Experienced a Treatment-emergent Adverse Event","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"490","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":26,"n":768},"commonTop":["Nausea","Constipation","Vomiting"]}}}